Peroxidases Inhibitors
Peroxidases are a diverse group of enzymes that catalyze the reduction of hydrogen peroxide and other organic hydroperoxides, often using various electron donors to generate reactive oxygen species (ROS) or other oxidized products. In humans, the most prominent members of this family include myeloperoxidase (MPO), eosinophil peroxidase (EPO), and thyroid peroxidase (TPO). These enzymes play critical roles in innate immunity and hormone synthesis; however, their dysregulation is linked to a wide range of inflammatory and oxidative stress-related diseases. MPO, primarily found in neutrophils, produces hypochlorous acid (HOCl), a potent oxidant that can cause significant tissue damage if not properly regulated. Elevated MPO levels are strongly associated with cardiovascular diseases, such as atherosclerosis and heart failure, as well as neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases.
Similarly, EPO is involved in the pathogenesis of asthma and allergic inflammation, while TPO is a key target in autoimmune thyroiditis. The development of peroxidase inhibitors, particularly those targeting MPO, has seen substantial progress in recent years. Several small-molecule inhibitors are currently in various stages of clinical development. For example, AZD4831 and PF-06667804 are potent MPO inhibitors that have been evaluated in clinical trials for their potential to treat heart failure with preserved ejection fraction (HFpEF) and other cardiovascular conditions. These inhibitors are generally classified into two categories: irreversible suicide substrates that bind to the heme group and reversible inhibitors that compete with the substrate for the active site.
A significant challenge in the development of peroxidase inhibitors is achieving high selectivity to avoid interfering with essential physiological processes, such as thyroid hormone synthesis by TPO or the microbicidal activity of MPO during acute infections. Furthermore, the high reactivity of the oxidants produced by these enzymes makes it difficult to quantify the direct impact of inhibition in vivo. Research is also exploring the use of peroxidase inhibitors in combination with antioxidant therapies to provide a more comprehensive approach to reducing oxidative damage. As clinical trials progress, the results will provide critical insights into the safety and efficacy of these compounds, potentially leading to new treatments for chronic inflammatory diseases. The continued exploration of the structural biology of Peroxidases will also facilitate the design of next-generation inhibitors with improved potency and reduced off-target effects, further expanding the therapeutic potential of this enzyme class.
Ultimately, the goal is to develop inhibitors that can selectively dampen pathological oxidative stress without compromising the host's immune defense mechanisms.
